Cancer Archives

mission therapeutics sachs interview zurich labiotech biotech

News and Trends 16 Mar 2016

Interviewing the Biotech which raised the Biggest European Round in 2016 so far

Yesterday I flew to Switzerland for the day, to gage what was going on at the 9th Annual Sachs conference for European Biotech CEOs. Here I had the chance to Interview Cambridge UK’s Mission Therapeutics on investment and technology.. Panel discussions covered Partnering and Investment for various therapeutic platforms – in MedTech, Diagnostics and generally ‘Israel’ (and […]

March 16, 2016 - 1 minutemin - By Philip Hemme

nanobiotix private placement €21M nanoxray sarcoma liver head neck prostate cancer nbtxr3 nanomedicine radiotherapy localized

News and Trends 15 Mar 2016

French Nanomedicine Biotech Gets €21M to Kill Cancer with ‘Beam Rays’

Nanobiotix (France) has had a successful private placement in, raising €21.3M to advance the clinical development of its localised radiotherapy for Cancer. Located in Paris’ superbiocluster, Nanobiotix wants to change the way cancer is treated – but in a different way from most Biotech strategies. It is developing NanoXRay, a paradigm-shifting nanotechnology for localised radiotherapy. Nanobiotix has […]

March 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

nature cancer reviews lumd leiden isa pharmaceuticals immuno oncology immunotherapies checkpointblocking chemotherapy immunosupression

News and Trends 11 Mar 2016

Reviewing Immuno-Oncology: What works and what doesn’t

Researchers from Leiden University Medical Center (LUMC) and ISA Pharmaceuticals (Netherlands) have authored an extensive review of what is working in immuno-oncology – and what hasn’t. The review was accepted in the well-known journal Nature Reviews Cancer and it covers the findings of 250 peer-reviewed papers about immunotherapies. Immuno-oncology is radically changing the way cancer is being […]

March 11, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 11 Mar 2016

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

From East to West, this week we say goodbye to Hungary and head up towards Queen Elizabeth II’s United Kingdom. Cambridge, known for its World renowned Academia is where Mission Therapeutics, our Biotech of the Week is located. City: Cambridge (UK) Founded: 2011 Employees: 30 Total raised: €110M (as of 02/2016) CEO: Anker Lundemose Mission: Founded in 2011, Mission Therapeutics, […]

March 11, 2016 - 1 minutemin - By Joachim Eeckhout

aprea ovarian cancer p53 protein apr 246 karolinska versant ventures 5am ventures healthcap

News and Trends 10 Mar 2016

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

Aprea (Sweden) is not a well-know Biotech (yet), but has succeeded in raising €46M from big investors in the US and Europe. Why? For its First-in-class potential for a famous cancer target… Aprea started in 2003 as a spin-off from cancer research at Karolinska Institutet, in its technology-transfer program. This Biotech has a promising candidate […]

March 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

prime priority medicines ema european medicine agency breakthrough therapy fast track biotech

News and Trends 9 Mar 2016

EMA Launches its own Fast Track for Breakthrough Therapies

The European Medicine Agency (EMA) is launching a priority scheme for therapies addressing unmet medical needs, similar to the FDA’s fast track. The key objective is to help European patients get earlier access to therapies that could be lifesaving, and this could have significant impact on the European Biotech industry. This new PRIME fast-track will include a […]

March 9, 2016 - 2 minutesmins - By Denise Neves Gameiro

karolinska development akinion acute myeloid leukemia aml liver toxicity phase II akn 028 tyrosine kinase inhibitor

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M hit in its portfolio valuation. Sad news for Akinion. This Stockholm-based drug developer decided to halt the development of its lead candidate, APN-028. This happens after […]

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

cancer top 8 biotech immunooncology europe oncology

News and Trends 7 Mar 2016

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost… Simply by having a quick look through our articles, we can easily confirm that cancer is one of the World’s main concerns in […]

March 7, 2016 - 2 minutesmins - By Dani Bancroft

leukemia mesothelioma myeloma sellas cancer immunoncology fda wt1

News and Trends 2 Mar 2016

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

Sellas (Switzerland) is developing an immunotherapeutic cancer vaccine – which can be easier now that the FDA granted it Orphan Drug designations for two types of cancer (for the lung area and a type of leukemia). Sellas is a biopharma developing treatments for different cancers and diseases of the central nervous system (CNS). Its lead […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

win horizon centauri antibody avvinity cancer alphamer

News and Trends 2 Mar 2016

New Joint Venture to Shake Up Immuno-Oncology in the UK

Avvinity Therapeutics is the new child of two UK Biotechs: Horizon Discovery and Centauri. The goal? To create the ultimate immuno-oncology toolbox with€32M. Just created, Avvinity is a joint venture targeting the immuno-oncology field, which is worth around €32M – and is only expected to grow. The biotechnological approach to cancer treatments has many Pharma and Biotech companies interested, […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

exelixis ipsen cancercabozantinib renal liver endometrial nsclc

News and Trends 1 Mar 2016

French Ipsen closes €700M deal for Californian Cancer Drug

Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights for a multi-organ cancer candidate outside US, Canada and Japan. California-based Exelixis has found an European partner to license the small molecule drug, cabozantinib. Ipsen, a French biotech group, will have comercialization rights for cabozantinib worldwide, except in the US and […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 24 Feb 2016

German Biotech wins FDA Approval for New Liver Cancer Trial

4SC, in Germany, has the FDA’s green light to conduct efficacy trials in the US with a candidate drug against hepatocellular carcinoma. Munich-based 4SC’s lead candidate, resminostat, is a small-molecule being tested in several trials for some of the deadliest cancers. These include liver – which is also known as hepatocellular carcinoma (HCC). Resminostat is an inhibitor of histone […]

February 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us